COVID-19 infection risk in patients on immunosuppressive/immunomodulator therapy: A single center study

Dermatol Ther. 2021 Nov;34(6):e15126. doi: 10.1111/dth.15126. Epub 2021 Sep 19.

Authors

Maryam Ghiasi¹, Maryam Nasimi¹, Narges Ghandi¹, Vahideh Lajevardi¹, Robabeh Abedini¹, Arghavan Azizpour¹, Mahshid Sadat Ansari¹, Azita Kheiltash², Kamran Balighi¹

Affiliations

¹ Autoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
² Department of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

No abstract available

Publication types

Letter

MeSH terms

Adjuvants, Immunologic
COVID-19*
Humans
Immunologic Factors
Immunosuppressive Agents / adverse effects
SARS-CoV-2

Substances

Adjuvants, Immunologic
Immunologic Factors
Immunosuppressive Agents